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During the development of the production process for
a monoclonal antibody (mAb), we observed a significant
increase in the reduction of interchain disulfide bonds
following pilot scale protein A purification of the pro-
duced antibody (IgG1).Different companies have
reported the presence of fragmented IgG1 antibodies in
the clarified cell culture fluid (CCCF) at manufacturing
scale. It has been demonstrated [1] that enzymes of the
thioredoxin system, released during the decline phase of
the culture, were responsible for the interchain disulfide
bond reduction. However, our observations were differ-
ent as the majority of the interchain disulfide bonds were
still oxidized in the CCCF. The massive fragmentation of
interchain disulfide bonds occurred only after pilot scale
protein A purification step. This study presents our
insights in antibody reduction using scale-down models.
Experimental approach
First, the mAb fragmentation phenomenon was repro-
duced at small scale by incubation of mAb containing
CCCF with cell lysate followed by SDS-PAGE with and
without NEM (N-ethylmaleimide). NEM is known to
protect free thiol groups during sample preparation for
SDS-PAGE [2].
Second, a scale down model of the bioreactor process
was established in order to understand which process
parameters led to the massive reduction and hence frag-
mentation of the mAb during the pilot scale protein A
purification process.
Results and discussion
This study demonstrated first that the massive increase
in mAb fragmentation could be replicated experimen-
tally in small-scale when the antibody was subjected to
protein denaturing conditions. Fully oxidized antibodies
were observed in the CCCF using non-reducing SDS
PAGE with NEM (protecting the free thiol groups),
whereas without NEM, the interchain bonds of the anti-
bodies were massively reduced. We concluded from
these experiments that intradomain free thiols can
reduce interchain disulfide bonds by disulfide scram-
bling when these are exposed to denaturing conditions
during SDS-PAGE preparation or protein A elution at
pilot scale. We also demonstrated that the accumulation
of free thiols in the supernatant, observed at the start of
the decline phase, led to the increase of free intrado-
mainthiols in the mAb present in the CCCF at the end
of the culture. In parallel, the intracellular ratio GSH/
GSSG showed a sharp increase from day 7 onwards,
indicating a change in the intracellular redox potential
in the process. One hypothesis is that these accumulated
intracellular reductive forms were released in the super-
natant as soon as the viability decreased, leading to a
more reductive environment. The detailed mechanisms
responsible for this intracellular change remain unclear.
Figure 1 summarizes our understandings of the
phenomenon.
Conclusion
MAb reduction is a complex mechanism, which was
found in our case to be related to the upstream process
rather than a specific cell line. We observed this phe-
nomenon with two different IgG1 expressing CHO cell
lines in two different non-optimized processes, in which
the cell viability decreased quickly and sharply. As this* Correspondence: Julie.Ruaudel@glenmarkpharma.com
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viability decline was identified to be the root cause for
the release of thiols in the supernatant, the most evident
way to prevent the reduction phenomenon might be the
modification of the process conditions in order to main-
tain a good viability throughout the entire upstream
process until the clarification step. Further, different IgG
formats have been shown to have different sensitivities
to reduction [3], thus choosing the right IgG format
might be helpful to avoid reduction. The addition of
copper sulfate has been also identified as a treatment in
the literature [4]. Added at the beginning of the culture,
copper sulfate maintains the supernatant in an oxidative
state until the end of the culture and thus prevents an
increase of free thiols in the supernatant.
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Figure 1 Our current understanding of the process leading to mAb reduction during pilot scale protein A purification.
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